newsfilter
← Latest News
ClinicalTrials.gov·

ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE - NCT05746559

Number of Participants Experiencing Major Adverse Kidney Events (MAKE) (Based on serum Cystatin C [sCysC]) at Day 90 Post Cardiopulmonary Bypass (CPB), Number of Participants Free From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) at Day 90 Post CPB, Number of Participants Free From Severe CSA-AKI (Kidney Disease: Improving Global Outcomes [KDIGO] Stage 2 or 3) Based on Highest Observed Serum Creatinine (sCr) Within 7 Days Post CPB, (and 9 more...)